Barinthus Biotherapeutics (BRNS) EBIAT (2020 - 2025)
Historic EBIAT for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$14.6 million.
- Barinthus Biotherapeutics' EBIAT fell 7924.71% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.9 million, marking a year-over-year decrease of 3120.83%. This contributed to the annual value of -$61.2 million for FY2024, which is 1669.78% up from last year.
- Per Barinthus Biotherapeutics' latest filing, its EBIAT stood at -$14.6 million for Q3 2025, which was down 7924.71% from -$21.1 million recorded in Q2 2025.
- Barinthus Biotherapeutics' 5-year EBIAT high stood at $15.7 million for Q2 2022, and its period low was -$23.8 million during Q2 2023.
- For the 5-year period, Barinthus Biotherapeutics' EBIAT averaged around -$12.4 million, with its median value being -$15.5 million (2024).
- Per our database at Business Quant, Barinthus Biotherapeutics' EBIAT tumbled by 238500.0% in 2021 and then soared by 28035.01% in 2022.
- Over the past 5 years, Barinthus Biotherapeutics' EBIAT (Quarter) stood at -$15.2 million in 2021, then tumbled by 39.67% to -$21.2 million in 2022, then grew by 18.4% to -$17.3 million in 2023, then fell by 19.09% to -$20.6 million in 2024, then rose by 29.24% to -$14.6 million in 2025.
- Its last three reported values are -$14.6 million in Q3 2025, -$21.1 million for Q2 2025, and -$19.7 million during Q1 2025.